Sponsor content

Collaborative Research and Licensing Opportunity: Products for treatment and prevention of Ebola Zaire disease

Scientists at the NIAID Vaccine Research Center have developed human monoclonal neutralizing antibodies for treatment and prevention of Ebola Zaire disease.

Upvote 0 Comment

Scientists at the NIAID Vaccine Research Center have developed human monoclonal neutralizing antibodies for treatment and prevention of Ebola Zaire disease.  The monoclonal antibodies bind to different regions of the Ebola glycoprotein that are unique for these two mAbs. Alone or in combination, the mAbs prevent or reverse Ebola Zaire virus disease in non-human primates.  Nonclinical studies have demonstrated complete protection against disease with a single antibody and complete protection against viremia by addition of a second antibody. The current nonclinical pharmacology demonstrates a favorable pharmacokinetic profile and there is a first-in-time human clinical trial projected for 2017. The anticipated indications for this technology include pre-and post-symptomatic treatment, and pre-and post-exposure prophylaxis.

Potential Commercial Applications: 

  • Therapeutics
  • Diagnostics

Competitive Advantages: 

  • Favorable pharmacokinetic profile
  • Favorable manufacturing
  • Complete protection against disease with a single unique mAb
  • Complete protection with fewer administrations and/or lower doses than any other mAbs
  • Complete protection against viremia with two antibodies

Development Stage:    

  •  In vivo data available (animal) 
  •  Entering first-in-time human clinical trial (2017)

Inventors:  Nancy J. Sullivan, Barney S. Graham, Julie Ledgerwood, Daphne A. Stanley, all of NIAID; Antonio Lanzavecchia and Davide Corti,IRB; John Trefry, USAMRIID/WR                                 

Publications: 

Corti D, et al., Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody. Science. 2016 Mar 18;351:1339-42. [PMID: 26917593]

Misasi J, et al., Structural and molecular basis for Ebola virus neutralization by protective human antibodies. Science. 2016 Mar 18;3511343-6. [ PMID: 26917592].

Intellectual Property: 

HHS Reference No. E-045-2015—U.S. Provisional Application No. 62/087,087, filed December 3, 2014; PCT Application No. PCT/US2015/060733, filed November 13, 2015

Licensing and Collaborative Research Opportunity:The Technology Transfer and Intellectual Property Office (TTIPO) is seeking parties interested in licensing or collaborative research to further co-develop this technology. For opportunities, please contact

Go to the profile of NIAID Technology Transfer and Intellectual Property Office

NIAID Technology Transfer and Intellectual Property Office

NIAID’s technology transfer office, TTIPO, is a one-stop resource for organizations interested in partnering with NIAID to access, develop, and manage the translation of research discoveries into medically beneficial products. TTIPO seeks to expand NIAID’s innovation pipeline with existing and new partners in areas such as newly emerging and re-emerging infectious diseases (e.g., dengue, Zika, Ebola, influenza, methicillin-resistant Staphylococcus aureus and HIV/AIDS), biodefense (e.g., smallpox and anthrax), and immune-mediated diseases (e.g., asthma and allergy).
20 Contributions
13 Followers
1 Following

Please sign in or register for FREE to comment